Overcome HTRF detection challenges with optimised microplate reader settings and simplified analysis.
List view / Grid view
Discover the possibilities opened up by HTRF cytokine assays in an autoimmune context.
Webinar: Optimised workflow for rapid identification of neutralising antibodies against viral particles
Helping in the race to identify effective neutralising antibodies against the spike protein of SARS-CoV-2 virus as the COVID-19 global death rate continues to rise.
The essential guide for extending your knowledge on the molecular mechanisms of neurodegenerative diseases
Electrophysiology and Biophysics Laboratory Techniques Guide from Molecular Devices.
This review highlights five recent publications about homogeneous assays applied to PROTACs, a chemical knockdown approach for cancer research.
Many anti-angiogenic drugs have been developed to use in cancer therapy, while pro-angiogenic molecules may hold potential in regenerative applications.
Learn how to gain insights and expedite studies for 2D and 3D cellular structures with affordable automated cellular imaging.
Achieve FDA 21 CFR Part 11 compliance with SoftMax® Pro GxP Software.
Discover how absorbance detection works as well as different types of absorbance-based assay applications that scientists can utilise for their research.
Molecular Devices helps Recursion produce the largest publicly available set of human cellular morphological data for COVID-19 therapeutic research.
A powerful, yet affordable, high-content imaging system in your own lab.
Discover how you can simplify your workflow by combining microplate reading and imaging in a small footprint.
Whitepaper: Evaluation of the analytical performance of the AQUIOS CL flow cytometer in a multi‑centre study
This whitepaper from Beckman Coulter evaluates the analytical performance of the AQUIOS CL flow cytometer in a multi‑centre study.
Horizon Discovery have developed their 3D OncoSignature™ spheroid screening service that consists of a panel of 200 cell lines. In this application note they demonstrate the ability of parallel 2D and 3D OncoSignature primary screens to identify known compounds with enhanced activity under 3D conditions.